Composition, kit and method for inhibition of IL-21 mediated activation of human cells
A synergistic composition, kit and method for inhibition and/or neutralization of IL-21 mediated activation of human cells including (i) a first agent being an antibody or antibody fragment thereof directed to a first epitope of IL-21, and (ii) a second agent being an antibody or antibody fragment thereof directed to a second epitope of IL-21 is disclosed. The inhibition and/or neutralization of IL-21 mediated activation of human cells is for use in the prophylaxis and/or treatment of disease of immune-related conditions including inflammatory disease, autoimmunity and lymphomas.
1. A composition for inhibition and/or neutralization of interleukin-21 (IL-21) mediated activation of human cells comprising:
(i) a first agent directed to a first epitope of IL-21, the first agent being an IL-21 binding antibody or antibody fragment thereof, comprising the six complementarity determining regions (CDRs) of monoclonal antibody MT 6 produced by the cell line MT21.6G deposited with the American Type Culture Center (ATCC) under Patent Deposit Number PTA-126046, and
(ii) a second agent directed to a second epitope of IL- 21 , the second agent being an IL-21 binding antibody or antibody fragment thereof, selected from the group consisting of an IL-21 binding antibody, or fragment thereof, comprising the six CDRs of monoclonal antibody MT3 produced by the cell line MT21.3m deposited with the ATCC under Patent Deposit Number PTA-126045, and an IL-21 binding antibody, or fragment thereof, comprising the six CDRs of monoclonal antibody MT5 produced by the cell line MT21.5 deposited with the ATCC under Patent Deposit Number PTA-126568,
wherein said composition is formulated with at least one pharmaceutically acceptable excipient.
2. The composition according to claim 1 , wherein said first and/or second agent comprises a fully human, chimeric or humanized antibody or a fragment of a fully human, chimeric or humanized antibody.
3. The composition according to claim 1 , wherein said second agent comprises the six CDRs of the monoclonal antibody MT3 produced by the cell line MT21.3m deposited with the ATCC under Patent Deposit Number PTA-126045.
4. The composition according to claim 3 , wherein (i) said first agent is a human, chimeric or humanized antibody or antibody fragment thereof, and (ii) said second agent is a human, chimeric or humanized antibody or antibody fragment thereof.
5. The composition according to claim 4 , wherein (i) said first agent is a chimeric or humanized antibody or antibody fragment thereof, and (ii) said second agent is a chimeric or humanized antibody or antibody fragment thereof.
6. The composition according to claim 1 , wherein said second agent comprises the six CDRs of the monoclonal antibody MT5 produced by the cell line MT21.5 deposited with the ATCC under Patent Deposit Number PTA-126568.
7. The composition according to claim 5 , wherein (i) said first agent is a human, chimeric or humanized antibody or antibody fragment thereof, and (ii) said second agent is a human, chimeric or humanized antibody or antibody fragment thereof.
8. The composition according to claim 5 , wherein (i) said first agent is a chimeric or humanized antibody or antibody fragment thereof, and (ii) said second agent is a chimeric or humanized antibody or antibody fragment thereof.
9. The composition according to claim 1 , wherein said first and second agents are is in the form of a bispecific antibody (bisAb), or fragment thereof, being able to bind both the first and second epitopes of IL-21.
10. The composition according to claim 1 , wherein said first and/or second agent is a Fab fragment, F(ab′)2 fragment, single chain Fv fragment or monovalent IgG.
11. The composition according to claim 1 , wherein said first epitope comprises:
the third helical region interacting with the IL-21 receptor chain, and
the last helical region that interacts with the common gamma chain.
12. The composition according to claim 1 , wherein said second epitope comprises:
the β-strand region (D).
13. A kit for inhibition and/or neutralization of interleukin-21 (IL-21) mediated activation of human cells comprising:
(i) a first agent directed to a first epitope of IL-21, the first agent being an IL-21 binding antibody, or a fragment thereof, comprising the six complementarity determining regions (CDRs) of monoclonal antibody MT6 produced by the cell line MT21.6G deposited with the American Type Culture Center (ATCC) under Patent Deposit Number PTA-126046, and
(ii) a second agent directed to a second epitope of IL-21, the second agent being an IL-21 binding antibody, or fragment thereof, selected from the group consisting of an IL-21 binding antibody, or fragment thereof, comprising the six CDRs of monoclonal antibody MT3 produced by the cell line MT21.3m deposited with the ATCC under Patent Deposit Number PTA-126045, and an IL-21 binding antibody, or fragment thereof, comprising the six CDRs of monoclonal antibody MT5 produced by the cell line MT21.5 deposited with the ATCC under Patent Deposit Number PTA-126568,
wherein said first and second agents are each formulated with at least one pharmaceutically acceptable excipient.
14. A method of inhibition and/or neutralization of interleukin-21 (IL-21) mediated activation of human cells in a subject diagnosed with a disease associated with IL- 21 production comprising the steps of administering to the subject (i) a first agent directed to one epitope of IL-21, the first agent being an IL- 21 binding antibody, or a fragment thereof, comprising the six complementarity determining regions (CDRs) of monoclonal antibody MT 6 produced by the cell line MT21.6G deposited with the American Type Culture Center (ATCC) under Patent Deposit Number PTA-126016 accession number, and (ii) a second agent directed to a second epitope of IL- 21 , the second agent being an IL-21 binding antibody, or fragment thereof, selected from the group consisting of an IL-21 binding antibody, or fragment thereof, comprising the six CDRs of monoclonal antibody MT 3 produced by the cell line MT21.3m deposited with the ATCC under Patent Deposit Number PTA-126045, and an IL-21 binding antibody, or fragment thereof, comprising the six CDRs of monoclonal antibody MT 5 produced by the cell line MT21.5 deposited with the ATCC under Patent Deposit Number PTA-126568, wherein said administration is simultaneous or sequential, and wherein the combined administering of said first and second agents has a synergistic neutralizing effect on IL-21 activation of cells for the treatment of a disease associated with IL-21 production.
15. The method according to claim 14 , wherein the disease associate with IL-21 production is a lymphoma or is an immune-related disease selected from inflammatory disease and autoimmunity.
16. The method according to claim 14 , wherein the immune-related disease is selected from the group consisting of systemic lupus erythematosus, rheumatoid arthritis, celiac disease, osteoarthritis, psoriatic arthritis, ankylosing spondylitis, transplant rejection, inflammatory bowel disease, psoriasis, cystic fibrosis and Crohn's disease.
17. The method according to claim 14 , wherein the first and second agents are administered simultaneously.
18. The method according to claim 14 , wherein the first and second agents are administered sequentially.
19. The method according to claim 14 , wherein said second agent comprises the six CDRs of the monoclonal antibody MT3 produced by the cell line MT21.3m deposited with the ATCC under Patent Deposit Number PTA-126045.
20. The method according to claim 14 , wherein said second agent comprises the six CDRs of the monoclonal antibody MT5 produced by the cell line MT21.5 deposited with the ATCC under Patent Deposit Number PTA-126568.